Public knowledge of benefits of breast and prostate cancer screening in Europe

Gerd Gigerenzer, Jutta Mata, Ronald Frank, Gerd Gigerenzer, Jutta Mata, Ronald Frank

Abstract

Making informed decisions about breast and prostate cancer screening requires knowledge of its benefits. However, country-specific information on public knowledge of the benefits of screening is lacking. Face-to-face computer-assisted personal interviews were conducted with 10,228 persons selected by a representative quota method in nine European countries (Austria, France, Germany, Italy, the Netherlands, Poland, Russia, Spain, and the United Kingdom) to assess perceptions of cancer-specific mortality reduction associated with mammography and prostate-specific antigen (PSA) screening. Participants were also queried on the extent to which they consulted 14 different sources of health information. Correlation coefficients between frequency of use of particular sources and the accuracy of estimates of screening benefit were calculated. Ninety-two percent of women overestimated the mortality reduction from mammography screening by at least one order of magnitude or reported that they did not know. Eighty-nine percent of men overestimated the benefits of PSA screening by a similar extent or did not know. Women and men aged 50-69 years, and thus targeted by screening programs, were not substantially better informed about the benefits of mammography and PSA screening, respectively, than men and women overall. Frequent consulting of physicians (r = .07, 95% confidence interval [CI] = 0.05 to 0.09) and health pamphlets (r = .06, 95% CI = 0.04 to 0.08) tended to increase rather than reduce overestimation. The vast majority of citizens in nine European countries systematically overestimate the benefits of mammography and PSA screening. In the countries investigated, physicians and other information sources appear to have little impact on improving citizens' perceptions of these benefits.

References

    1. Nyström L. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet. 2002;359(9310):909–919.
    1. Humphrey LL, Helfand M, Chan BKS, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137(5):347–360.
    1. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2006;(4):CD001877.
    1. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089–1096.
    1. Schwartz LM, Woloshin S, Fowler FJ, Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1):71–78.
    1. Welch HG. Should I Be Tested for Cancer? Berkeley, CA: University of California Press; 2004.
    1. U.S. Preventive Services Task Force. Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002;137(11):129–131.
    1. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166(1):38–43.
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–1328.
    1. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(3):1310–1319.
    1. World Health Statistics [database on the Internet] Geneva, Switzerland: World Health Organisation; 2008. . Accessed July 18, 2009.
    1. Binkowska M, Debski R. Screening mammography in Polish female population aged 45 to 54 [in Polish] Ginekol Pol. 2005;76(11):871–878.
    1. GfK-Nürnberg e.V., Frank R. Health in Europe. European Consumer Study 2007 [in German] Nuremberg, Germany: GfK-Nürnberg; 2007.
    1. Särndal C-E, Swensson B, Wretman J. Model Assisted Survey Sampling. 2nd ed. New York, NY: Springer-Verlag; 1992.
    1. Rozhkova NI, Kochetova GP. Analysis of equipment of the Russian X ray mammological service in 2003-2004. Biomed Eng. 2005;39(5):242–244.
    1. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients to make sense of health statistics. Psychol Sci Public Interest. 2007;8(2):53–96.
    1. Miller AM, Champion VL. Attitudes about breast cancer and mammography: racial, income, and educational differences. Women & Health. 1997;26(1):41–63.
    1. Price JH, Desmond SH, Slenker S, Smith DE, Stewart PW. Urban black women's perceptions of breast cancer and mammography. J Community Health. 1992;17(4):191–204.
    1. Domenighetti G, D'Avanzo B, Egger M, et al. Women's perception of the benefits of mammography screening: population-based survey in four countries. Int J Epidemiol. 2003;32(5):816–821.
    1. Black WC, Nease RF, Jr, Tosteson ANA. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87(10):720–731.
    1. Haggstrom DA, Schapira MM. Black-white differences in risk perceptions of breast cancer survival and screening mammography benefit. J Gen Intern Med. 2006;21(4):371–377.
    1. Steurer J, Held U, Schmidt M, Gigerenzer G, Tag B, Bachmann LM. Legal concerns trigger PSA testing. J Eval Clin Pract. 2009;15(2):390–392.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する